With box warnings

Without box warnings

Branded

Generic

3 results

lynparza
(olaparib)
AstraZeneca Pharmaceuticals LP
Usage: Lynparza is indicated for the maintenance treatment of BRCA-mutated advanced ovarian cancer, recurrent ovarian cancer, adjuvant treatment of high-risk early breast cancer, and metastatic breast cancer. Additionally, it treats HRR gene-mutated metastatic prostate cancer, often in combination with other therapies, using FDA-approved companion diagnostics for patient selection.
rubraca
(rucaparib)
Clovis Oncology, Inc.
Usage: Rubraca is indicated for maintenance treatment of adult patients with BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor therapy and taxane chemotherapy.
rubraca
(rucaparib)
pharmaand GmbH
Usage: Rubraca is indicated for the maintenance treatment of adults with BRCA-mutated recurrent ovarian cancer in response to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after previous treatments. Selection for therapy should be guided by an FDA-approved companion diagnostic.

Medications for Recurrent Ovarian Cancer

lynparza